To experimentally prove this, we chose three DLBCL cell lines with different genetic backgrounds, representing the heterogeneity of BECLIN-1 and BCL-2 expression (see Table 1 in Materials and Methods), to address whether and how autophagy modulation can impact the chemotherapy response. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.